单细胞测序市场一直的局面是10x Genomics一马当先，剩下各个品牌万马奔腾。对于数据表现，大家看到更多的是包括10x ...

Investing.com - BofA Securities将 10X Genomics (NASDAQ:TXG) 的目标价从18.00美元上调至21.00美元，同时维持"中性"评级，此举是基于该公司初步公布的第四季度业绩。新目标价略高于TXG目前20.46美元的股价，该股在过去一周内飙升11.7%，接近其52周高点20.72美元。

10X Genomics Inc (TXG) 股价达到52周高点20.36美元，这对这家生物技术公司来说是一个重要里程碑。根据 InvestingPro 数据显示，该股票表现出显著的波动性，贝塔系数为2.18，远高于市场平均水平。过去一年中，该股票经历了显著增长，一年变化率为29.46%。这一上升趋势反映了投资者对该公司创新基因组解决方案的信心和兴趣不断增强。过去一年的股票表现凸显了市场对10X ...

Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select ...

In January 2026, 10x Genomics, Inc. reported preliminary 2025 results showing about US$166.0 million in fourth-quarter ...

KNOXVILLE, TN, UNITED STATES, January 8, 2026 /EINPresswire.com/ -- Daisy Genomics Inc. (“Daisy Genomics”) and New Day ...

Demonstrating faster, simpler, more cost-efficient NGS workflows that turn complex agrigenomics data into practical ...

Forbes contributors publish independent expert analyses and insights. Steven covers accessibility and assistive technologies. Aug 07, 2023, 01:54pm EDT Aug 07, 2023, 03:58pm EDT This article is more ...

What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 4.7% in the afternoon session after the company ...

Mapping the genomes of the bacteria responsible for yaws, a debilitating childhood disease, has uncovered new insights into ...